Regimen Protocols

MM Regimen Protocols

To support you in using the most appropriate therapies for your patients with multiple myeloma, Managing Myeloma has worked with clinical experts to develop this protocol series. Each protocol focuses on the latest information from clinical trials on prescribing, administering and monitoring a new agent or regimen. In these practice resources, you’ll find comprehensive, referenced guidance in the safe and effective use of therapies for your patients with this disease.

Download Regimen Protocols Below
•  CyBorD: Cyclophosphamide/bortezomib/dexamethasone
•  KPD: Carfilzomib/Pomalidomide/Dexamethasone Previously Treated Multiple Myeloma
•  KRD: Previously Treated Myeloma; Primary Therapy for Newly Diagnosed, Transplant Eligible Myeloma Patients
•  RVD: Primary (induction) and Consolidation Therapy in Transplant Eligible Patients
•  RVD: Post-consolidation Maintenance Therapy in High-risk Myeloma
•  ELO-LD: Elotuzumab/lenalidomide/dexamethasone
•  IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
•  ELO-VD: Elotuzumab/Bortezomib/Dexamethasone
•  Ld–continuous: Lenalidomide/Dexamethasone
•  POM-VD: Pomalidomide/Bortezomib/Dexamethasone
•  Dara-LD: Daratumumab/Lenalidomide/Dexamethasone
•  VD-Pan: Bortezomib/Dexamethasone/Panobinostat


Reviewed on January 17, 2017 for clinical relevance.

Last modified: February 8, 2017